Evaluating the Ability of Zoledronic Acid to Reduce the Rate of Subsequent Osteoporotic Fractures After a Hip Fracture

Completed · Phase 3

Conditions studied: Osteoporosis, Hip Fracture

In brief

The purpose of this study is to evaluate whether zoledronic acid given once yearly for two years to men and women after surgical repair of a recent hip fracture will significantly reduce the rate of all re-occurring (new) osteoporotic fractures. All patients will receive vitamin D and calcium.

Key facts

Study ID

NCT00046254

Run by

Novartis Pharmaceuticals

People needed

2127

Starts

2002-02-01

Expected to finish

2007-02-01

Last updated by the study team

2012-05-02

Who can join

Age: 50 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Male or female ages 50 years or older
• Must have a recent hip fracture repair in the past 90 days
• Must be able to walk with or without assistive device (for example, using a walker) prior to the hip fracture

You may not qualify if…

• Current bisphosphonate users such as aredia (pamidronate), didronel (etidronate), fosamax (alendronate), actonel (residronate), skelid (tiludronate)
• Other protocol-defined inclusion/exclusion criteria may apply.

Where it is running

• University of Alabama Hospital — Birmingham, Alabama, United States
• Osteoporosis Diagnostic Center — Eureka, California, United States
• Sharp Grossmont Hosptial — La Mesa, California, United States
• The Permanente Group — Santa Rosa, California, United States
• Radiant Research Lake Worth — Lake Worth, Florida, United States
• Atlanta Resarch Center — Decatur, Georgia, United States
• United Osteoporosis Center Health Services — Gainesville, Georgia, United States
• Galesburg Orthopedic Services LTD — Galesburg, Illinois, United States
• Illinois Bone and Joint Institute — Morton Grove, Illinois, United States
• Mercy Arthritis and Osteoporosis Center — Des Moines, Iowa, United States
• Maine Medical Center Research Institute — Portland, Maine, United States
• University of Maryland School of Medicine — Baltimore, Maryland, United States
• Wayne State University, Div. of Endocrinology — Detroit, Michigan, United States
• Health East Osteoporosis Service — Woodbury, Minnesota, United States
• Highland Hospital — Rochester, New York, United States
• University of North Carolina Hospital — Chapel Hill, North Carolina, United States
• Duke University Health System — Durham, North Carolina, United States
• University Orthopaedics — Canfield, Ohio, United States
• Ohio State University — Columbus, Ohio, United States
• University of Pennsylvania Health System-Presbyterian Medical Center — Philadelphia, Pennsylvania, United States
• Saint Joseph Medical Center — West Reading, Pennsylvania, United States
• Saint Josephs — Warwick, Rhode Island, United States
• Palmetto Richland Memorial Hospital — Columbia, South Carolina, United States
• Seton Medical Center — Austin, Texas, United States
• St. Luke's Episcopal Hospital — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.